June 27, 2008

Multiple Myeloma Research Consortium (MMRC) Expands Model to Fifteen Member Institutions

The Multiple Myeloma Research Consortium (MMRC) today announced the addition of two Member Institutions. The new institutions, Indiana University Simon Cancer Center in Indianapolis and the University of California, San Francisco (UCSF), were selected following a highly competitive Request for Application (RFA) process.

The MMRC's current 13 Member Institutions are among the world's most prestigious academic research institutions. Indiana University and UCSF were selected to join the MMRC based on specific criteria, including their experience in conducting Phase I and Phase II clinical trials, their ability to enroll patients in these clinical trials, and the speed at which they are able to initiate clinical trials.

"As a results-driven organization focused on quality and efficiency, the MMRC holds its Member Institutions to the highest degree of accountability," said Kathy Giusti, Founder and Chief Executive Officer of the MMRC. "Indiana University and UCSF are highly collaborative and committed to achieving our goals. We are excited to welcome them as Member Institutions."

"The MMRC is widely recognized as an optimal clinical research model and we are proud to join in them in their efforts to deliver better, more effective treatments to patients," said Sherif Farag, MD, PhD, FRACP, FRCPA, Associate Professor of Medicine and Medical and Molecular Genetics Director, Indiana University School of Medicine.

"It is our privilege to join the MMRC in advancing high-quality clinical trials and in bringing patients effective new and combination treatments as quickly as possible," said Jeffrey Wolf, MD, Clinical Professor of Medicine, Director of Myeloma Program and Director of Clinical Research for Hematologic Malignancies, University of California, San Francisco,

About Multiple Myeloma

Multiple myeloma is an incurable cancer of the plasma cell. The five-year relative survival rate for multiple myeloma is approximately 33%, one of the lowest of all cancers. In 2007, an estimated 19,900 adults (10,960 men and 8,940 women) in the United States were diagnosed with multiple myeloma and an estimated 10,790 people died from the disease.

About the Multiple Myeloma Research Consortium (MMRC)

The MMRC, a 509a3 organization, was founded in 2004 by Kathy Giusti, a myeloma patient and Founder and Chief Executive Officer of the Multiple Myeloma Research Foundation (MMRF), to accelerate the development of novel and combination treatments for patients with multiple myeloma by facilitating innovative clinical trials and correlative studies.

At the core of the MMRC model is an exceptional Executive Committee, based in Norwalk, Conn., which provides strategic oversight of the MMRC's drug development drug projects. The MMRC's 15 Member Institutions are among the prominent academic research centers worldwide: City of Hope, Dana-Farber Cancer Institute, Emory University's Winship Cancer Institute, the Cancer Center at Hackensack University Medical Center, H. Lee Moffitt Cancer Center & Research Institute, Indiana University, Mayo Clinic, Ohio State University, Roswell Park Cancer Institute, St. Vincent's Comprehensive Cancer Center of Saint Vincent Catholic Medical Centers of New York, University Health Network (Princess Margaret Hospital), University of Chicago, University of Michigan, University of California - San Francisco, and Washington University.

The MMRC model also includes an advanced Tissue and Data Bank, which serve as a "bridge" between laboratory and clinical research conducted by the MMRC and a vital resource in advancing MMRC clinical trials and correlative science studies.

As a results-driven organization, the MMRC has facilitated to date 14 Phase I and II clinical trials of the most promising novel compounds and combination approaches. MMRC clinical trials are designed to include correlative studies to better understand what drugs are most effective in treating various sub-groups of myeloma patients, laying the foundation for the eventual development of personalized medicines as a treatment for myeloma.

For more information, please visit www.themmrc.org.